1-isopropyl-3-phenyl-pyrrolidine-2,5-dione | 58456-43-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-isopropyl-3-phenyl-pyrrolidine-2,5-dione
• 英文别名: 1-Isopropyl-3-phenyl-pyrrolidin-2,5-dion；3-Phenyl-1-propan-2-ylpyrrolidine-2,5-dione
• CAS: 58456-43-2
• 化学式: C₁₃H₁₅NO₂
• 分子量: 217.268
• InChiKey: WXEYFOFZONZLRN-UHFFFAOYSA-N

物化性质

• 沸点：
  366.6±31.0 °C(Predicted)
• 密度：
  1.149±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯基丁二酸 、 异丙胺 在 水 作用下， 生成 1-isopropyl-3-phenyl-pyrrolidine-2,5-dione
  参考文献：
  名称：

  Anticonvulsants. I. An Investigation of N-R-α-R₁-α-Phenylsuccinimides

  摘要：

  DOI：

  10.1021/ja01154a126

文献信息

• DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS
  申请人：Rutgers, The State University of New Jersey

  公开号：US20180148408A1

  公开（公告）日：2018-05-31

  A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.

  通过高通量筛选和引物开发的方法，识别化合物作为Keap1-Nrf2相互作用的直接抑制剂。Keap1-Nrf2相互作用的直接抑制剂比现有的间接抑制剂更具特异性，不受各种不良影响，并且是化学预防和治疗各种涉及氧化应激和/或炎症的疾病或症状的潜在药物候选者，包括但不限于癌症、糖尿病、阿尔茨海默病和帕金森病。还公开了识别新化合物以及使用所识别的新化合物或含有这些化合物的组合物来预防或治疗与Keap1-Nrf2相互作用活性相关的疾病或症状的方法。
• US20140256767A1
  申请人：——

  公开号：US20140256767A1

  公开（公告）日：2014-09-11
• FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF
  申请人：PharmAkea, Inc.

  公开号：US20170369443A1

  公开（公告）日：2017-12-28

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.